期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌患者口服特罗凯导致皮疹的临床护理研究

Nursing of oral tarceva on the non - small - cell lung cancer patients
下载PDF
导出
摘要 目的总结特罗凯治疗非小细胞肺癌（NSCLC）导致皮疹的护理经验。方法本文观察23例晚期肺癌口服特罗凯导致皮疹的患者，给予心理支持和对症临床护理。结果23例患者出现了不同程度的皮疹，且皮疹的严重程度、部位有较大差异。无因药疹而停药和死亡病例。结论加强药物皮疹的宣传教育，及时发现和处理皮疹，能避免和减少药物严重副作用，从而提高治疗效果及患者生活质量。 Objective To summary the nursing experience of nursing of oral tarceva on the non - small - cell lung cancer patients. Methods 23 cases of oral tareeva with NSCLC were observed, consist of psychological support and clinical nursing. Results All cases showed different degree rash, no one died. The severe level and location of rash performed significant difference. Conclusion To stengthern publication of rash, and discover and treat promptly, which could prevent and reduce the serious side effect of drugs and enhance therapeutic efficacy and quality of life.
作者 黄敏
机构地区 深圳市人民医院胸外科
出处 《中外医学研究》 2010年第11期110-111,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 特罗凯 非小细胞肺癌 皮疹 护理 Tarceva Non - small - cell lung cancer Rash Nursing
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Perez-Soler R,Delord JP,Halpern A,et al.HER1/EGFR inhibitor-associated rash:future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.Oncologist,2005,10(5):345-356.
  • 2陈振东,卜丽佳,吴秀伟,杜瀛瀛.表皮生长因子受体抑制剂引起的皮肤毒性：诊断与处理[J].癌症进展,2007,5(6):567-571. 被引量：20
  • 3Lacouture ME.Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer,2006,6(10):803-812.
  • 4Hidalgo M,Siu L,Nemunaitis J,et al.Phase I and pharmacologic study of OSI-774,an epidermal growth factor receptor tyrosine kinase inhibitor,in patients with edvanced solid malignancies.J Clin Oncol,2001,19(13):3267-3279.
  • 5Gamememr U,Pluzanska A.Results of a phase Ⅲ trial of edotimb(OSI-774) combined with cisplatin and gemcitabine(GC)chemotherapy in advanced non-small cell lung cancer(NSCLC).Proc Am Soc Clin Oncol,2004,22(14S):619S.
  • 6Perez-Soler R,Chachoua A,Hawanond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol,2004,22(16):3238-3247.
  • 7Johnson JR,Cohen M,Sridhara R,et al.Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regimen.Clin Cancer Res,2005,11(18):6414-6421.
  • 8Shepherd FA,Rodrigues Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med,2005,353(2):123-132.
  • 9Gatzemeier U,Pluzanska A,Szczesna A,et al.Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer:the tarceva lung cancer investigation trial.J Clin Oncol,2007,25(12):1545-1552.
  • 10Herbst RS,Prager D,Hermann R,et al.Tribute:a phase Ⅲ trial of erlotinib hydrochloride(OSI-774)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.J Clin Oncol,2005,23(25):5892-5899.

二级参考文献22

  • 1[1]Lynch TJ Jr,Kim ES,Eaby B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:An evolving paradigm in clinical management.Oncologist,2007,12 (5):610
  • 2[2]Lacouture ME.Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer,2006,6 (10):803
  • 3[3]Agero AL,Dusza SW,Benvenuto-Andrade C,et al.Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol,2006,55(4):657
  • 4[4]Rhee J,Oishi K,Garey J,et al.Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.Clin Colorectal Cancer,2005,5(Suppl 2):S101
  • 5[5]Molinari E,De Quatrebarbes J,Andre T,et al.Cetuximab-induced acne.Dermatology,2005,211 (4):330
  • 6[6]Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol,2004,22 (16):3238
  • 7[7]Robert C,Soria JC,Spatz A,et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies.Lancet Oncol,2005,6 (7):491
  • 8[8]Segaert S,Van Cutsem E.Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.Ann Oncol,2005,16(9):1425
  • 9[9]Jost M,Kari C,Rodeck U.The EGF receptor:An essential regulator of multiple epidermal functions.Eur J Dermatol,2000,10 (7):505
  • 10[10]Mimeault M,Bonenfant D,Batra SK.New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation,disorders and cancers.Skin Pharmacol Physiol,2004,17 (4):153

共引文献19

中外医学研究
2010年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部